# Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

> **NCT02514213** · PHASE1 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** 2mg INO-5150 and electroporation device CELLECTRA®-5P
- **BIOLOGICAL:** 8.5mg INO-5150 and electroporation device CELLECTRA®-5P
- **BIOLOGICAL:** 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
- **BIOLOGICAL:** 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
- **DEVICE:** Electroporation using CELLECTRA®-5P

## Key facts

- **NCT ID:** NCT02514213
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-12-12
- **Final completion:** 2017-12-12
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2017-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02514213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02514213, "Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02514213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*